Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
J. health med. sci. (Print) ; 7(1): 45-52, ene.-mar. 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1380381

ABSTRACT

El Perfil de egreso constituye un modelo teórico y la imagen del profesional que la institución de educación superior aspira formar. Es un conjunto de atributos que son certificados y le permiten a una persona ser reconocida y aceptada por la sociedad como profesional. La emergencia de estándares de calidad, utilizados por las agencias de acreditación de carreras universitarias, hoy exigen la necesidad de evaluar y rendir cuentas acerca del logro de las competencias establecidas y declaradas en el perfil de egreso, sin embargo, hay escasa evidencia concreta que demuestre modelos operativos de cómo abordar ese proceso de evaluación en distintos programas. Dada la relevancia del Perfil de Egreso de una carrera de pregrado y considerando que constituye el eje fundamental para el desarrollo curricular de los programas educativos, para realizar el proceso de autoevaluación y la posterior acreditación de las carreras, diseñamos e implementamos un modelo de seguimiento del cumplimiento del perfil de egreso en el plan de estudios de las carreras de la Facultad de Medicina de la Universidad Finis Terrae.


The Graduate Profile constitutes the theoretical model and the professional image that higher education aspires to form. It is a set of certified attributes and allows a person to be recognized and accepted by society as a professional. The emergence of quality standards, used by university careers' accreditation agencies, demands the need to evaluate and be accountable for achieving the competencies established and declared in the Graduate Profile. However, the is limited concrete evidence to demonstrate operational models of how to approach this evaluation process in different programs. Given the relevance of the Graduate Profile of an undergraduate career and considering that it constitutes the fundamental axis for the curricular development of educational programs, to carry out the self-evaluation process and the subsequent accreditation of the degrees, we design and implement a model for monitoring the compliance with the graduation profile in the study plan of the Faculty of Medicine of Universidad Finis Terrae.


Subject(s)
Humans , Professional Competence , Education, Medical, Graduate , Employment , Students, Health Occupations , Process Assessment, Health Care , Models, Theoretical
2.
Rev. méd. Chile ; 137(5): 634-640, mayo 2009. tab
Article in Spanish | LILACS | ID: lil-521865

ABSTRACT

Background: The study RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that Losartan was more effective lo reduce the progression of kidney disease in diabetic patients with proteinuria and a reduction in glomerular filtration rate. Aim: To perform a cost benefit analysis of Losartan use from provider and payer points of view. Material and methods: Published data of the RENAAL study was analyzed. The costs of the use or not use of Losartan in patients with diabetic nephropathy were compared in terms of total costs of the disease including medications, hospital admissions for myocardial infarction, cerebrovascular accidents and congestive cardiac failure and the costs of chronic hemodialysis. Results: The reduction in antihypertensive medication use, hospital admissions, and the delay in dialysis requirement from a mean of 65 to 79 months induced by Losartan use, results in net savings of $7,576,135 per patient, at 3.5 years of intervention. The figure does not change using different sensitivity scenarios. Conclusions: The eventual use of Losartan in type 2 diabetic patients results in important savings.


Subject(s)
Humans , Angiotensin II Type 1 Receptor Blockers/economics , /drug therapy , Diabetic Nephropathies/drug therapy , Losartan/economics , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Chile , Cost of Illness , Cost-Benefit Analysis , Kidney Failure, Chronic/economics , Kidney Failure, Chronic/prevention & control , Losartan/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL